title: [A survival analysis of patients with early-stage hepatocellular carcinoma fulfilling Milan criteria and undergoing hepatectomy].
abstract: OBJECTIVE
  To summarize the experience of hepatectomy in patients with hepatocellular carcinoma fulfilling the Milan criteria and analyze the clinicopathological factors for patient survival and tumor recurrence.
  
  
  METHODS
  The clinicopathological data of 104 patients with early-stage hepatocellular carcinoma fulfilling the Milan criteria and underwent hepatectomy at Peking Union Medical College Hospital between April 2003 and June 2009 were retrospectively analyzed.
  
  
  RESULTS
  The median follow-up was 24 months. There were 54 recurrent cases. The 1-, 3- and 5-year cumulative disease-free survival rate were 63.0%, 32.6% and 22.4% respectively. Neither univariate analysis nor multivariate analysis indicated any factor significantly correlated with recurrence (P>0.05). The cumulative overall survival rate at 1, 3 and 5 years were 88.8%, 68.1% and 68.1% respectively. Univariate analysis revealed that blood transfusion (P=0.000), involvement of hepatic capsule (P=0.000) and postoperative transarterial chemotherapy (P=0.049) were significantly correlated with survival. And multivariate analysis indicated that blood transfusion (P=0.001) and involvement of hepatic capsule (P=0.000) were independent prognostic factors for survival.
  
  
  CONCLUSIONS
  For the patients with early-stage hepatocellular carcinoma and compensated liver function fulfilling the Milan criteria, hepatectomy serves as the preferred treatment strategy.
authors.affiliation: Department of Hepatic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
authors.forename: Li-guo
authors.initials: LG
authors.lastname: Liu
authors.forename: Ruo-yu
authors.initials: RY
authors.lastname: Miao
authors.forename: Xin
authors.initials: X
authors.lastname: Lu
authors.forename: Yi-yao
authors.initials: YY
authors.lastname: Xu
authors.forename: Shun-da
authors.initials: SD
authors.lastname: Du
authors.forename: Hai-feng
authors.initials: HF
authors.lastname: Xu
authors.forename: Tian-yi
authors.initials: TY
authors.lastname: Chi
authors.forename: Hua-yu
authors.initials: HY
authors.lastname: Yang
authors.forename: Zhi-ying
authors.initials: ZY
authors.lastname: Yang
authors.forename: Yi-lei
authors.initials: YL
authors.lastname: Mao
authors.forename: Xin-ting
authors.initials: XT
authors.lastname: Sang
authors.forename: Shou-xian
authors.initials: SX
authors.lastname: Zhong
authors.forename: Jie-fu
authors.initials: JF
authors.lastname: Huang
authors.forename: Hai-tao
authors.initials: HT
authors.lastname: Zhao
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D018572:Disease-Free Survival; D005260:Female; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D016019:Survival Analysis